Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these Continue reading QIDP Antibiotics – 2015 Year-End Update
Any FDA meeting is a high-stakes game for industry: One never knows how the discussions will go. Some oddball issue may take center stage and usurp much time, creating an unbalanced perspective. At other times, simple issues seem to create Continue reading The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?
When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited data, often considered incomplete by today’s standards. Take colistin Continue reading Nitrofurantoin – An Old Drug Resurrected Needs Prospective Scrutiny
Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg . In Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)
When Al Gore became a best-selling author with “An Inconvenient Truth” he warned about climate change. When it comes to antibiotic resistance and the current situation of “Bad Bugs, No Drugs”, there are many voices warning us about a return Continue reading An Inconvenient Truth: Ciprofloxacin-Resistant Campylobacter